Lantern Pharma, is a pharmaceutical company that uses AI and ML to rescue "failed" cancer drugs. The clinical-stage pharmaceutical company is developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques, genomic data, and precision oncology trials. Lantern Pharma recognizes that the high cost and low success rates in oncology drug development largely stem from the inability to appropriately stratify patient populations prior to enrollment, and also from the inability to fully elucidate mechanisms of action that can suggest potent combinations. The startup's approach leverages its RADR(TM) platform to provide rapid, meaningful insight to both of these central problems in oncology. Lantern is also focused on accelerating personalized cancer therapy development through the use of AI and genomic-based patient stratification. I invited Panna Sharma, Chief Executive Officer, and President of Lantern Pharma onto my daily tech podcast to learn more about how much of a critical role technology is and will continue to play in the fight against cancer.